

Katherine S Panageas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5550077/publications.pdf>

Version: 2024-02-01

98
papers

7,549
citations

94433

37
h-index

58581

82
g-index

101
all docs

101
docs citations

101
times ranked

13956
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 419-426.	6.3	15
2	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
3	Symptoms, Surgical Events, and Length of Stay of Surgical Oncology Outpatients. <i>Journal of Perianesthesia Nursing</i> , 2022, , .	0.7	1
4	Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases. <i>Journal of Neuro-Oncology</i> , 2022, 157, 81-90.	2.9	16
5	Rosaiâ€Dorfmanâ€Destombes disease of the nervous system: a systematic literature review. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 92.	2.7	6
6	Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists. <i>Journal of Neuro-Oncology</i> , 2022, 158, 69-79.	2.9	7
7	Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 761-768.	2.5	11
8	Durable 5-year local control for resected brain metastases with early adjuvant SRS: the effect of timing on intended-field control. <i>Neuro-Oncology Practice</i> , 2021, 8, 278-289.	1.6	22
9	Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. <i>Cancer</i> , 2021, 127, 2062-2073.	4.1	40
10	Electronic Medical Record Documentation and Provider Burnout. <i>JCO Oncology Practice</i> , 2021, 17, 158-159.	2.9	2
11	Apples and Oranges? Considerations for EHR-Based Analyses Aggregating Data From Interventional Clinical Trials and Point-of-Care Encounters in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 21-23.	2.1	0
12	Cancer and Clot. <i>JACC: CardioOncology</i> , 2021, 3, 219-220.	4.0	1
13	Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. <i>Neurology</i> , 2021, 96, 1091-1093.	1.1	3
14	Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors. <i>JAMA Oncology</i> , 2021, 7, 720.	7.1	68
15	Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 9031-9038.	1.5	0
16	ASO Visual Abstract: Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 470-471.	1.5	0
17	The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. <i>Journal of Neuro-Oncology</i> , 2021, 153, 507-518.	2.9	20
18	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ TâCell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9.	16.8	93

#	ARTICLE	IF	CITATIONS
19	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Nonâ€“Small Cell Lung or Colorectal Cancer. JAMA Network Open, 2021, 4, e2117547.	5.9	20
20	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	12.4	54
21	Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes. Journal of Neuro-Oncology, 2021, 154, 301-313.	2.9	8
22	Acupuncture for Cancer Survivorsâ€“Reply. JAMA Oncology, 2021, 7, 1400.	7.1	0
23	Employing competing risks analysis in an aging population where many patients die from other causes. Journal of Geriatric Oncology, 2021, , .	1.0	0
24	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research, 2021, 27, 2226-2235.	7.0	25
25	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
26	Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation. Journal of Neuro-Oncology, 2021, 155, 277-286.	2.9	16
27	Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study. Neuro-Oncology Advances, 2021, 3, vdaa159.	0.7	7
28	High neutrophilâ€“toâ€“lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PDâ€“1 inhibitor monotherapy. Cancer, 2020, 126, 76-85.	4.1	92
29	Assessment of variation in 30â€“day mortality following cancer surgeries among older adults across US hospitals. Cancer Medicine, 2020, 9, 1648-1660.	2.8	5
30	Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma Research, 2020, 30, 71-75.	1.2	20
31	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology, 2020, 27, 1180-1188.	1.5	39
32	Assessing whether cancer stage is needed to evaluate measures of hospital surgical performance. Journal of Evaluation in Clinical Practice, 2020, 26, 66-71.	1.8	2
33	Linked Entity Attribute Pair (LEAP): A Harmonization Framework for Data Pooling. JCO Clinical Cancer Informatics, 2020, 4, 691-699.	2.1	2
34	Personalized electro-acupuncture versus auricular-acupuncture comparative effectiveness (PEACE): A protocol of a randomized controlled trial for chronic musculoskeletal pain in cancer survivors. Medicine (United States), 2020, 99, e20085.	1.0	14
35	Implications for Design and Analyses of Oncology Clinical Trials During the COVID-19 Pandemic. JAMA Oncology, 2020, 6, 1326.	7.1	11
36	The unique burden of rare cancer caregiving: caregivers of patients with Erdheimâ€“Chester disease. Leukemia and Lymphoma, 2020, 61, 1406-1417.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. <i>Neuro-Oncology</i> , 2020, 22, 979-992.	1.2	31
38	Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. <i>Journal of Neuro-Oncology</i> , 2019, 144, 553-562.	2.9	48
39	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 403-407.	2.9	55
40	Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survival. <i>Journal of Hospital Management and Health Policy</i> , 2019, 3, 8-8.	0.4	1
41	An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. <i>Nature Cell Biology</i> , 2019, 21, 203-213.	10.3	38
42	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. <i>Nature</i> , 2019, 565, 654-658.	27.8	361
43	EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 337-345.	2.9	30
44	Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. <i>Journal of Experimental Medicine</i> , 2019, 216, 2701-2713.	8.5	82
45	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. <i>Blood</i> , 2019, 133, 436-445.	1.4	159
46	Arterial thromboembolic events preceding the diagnosis of cancer in older persons. <i>Blood</i> , 2019, 133, 781-789.	1.4	127
47	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 3435-3447.	8.2	33
48	Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. <i>Annals of Surgical Oncology</i> , 2018, 25, 2172-2177.	1.5	16
49	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. <i>Clinical Cancer Research</i> , 2018, 24, 730-736.	7.0	16
50	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018, 4, 98.	7.1	125
51	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
52	Letter to the Editor Regarding "National Trends for Reoperation in Older Patients with Glioblastoma". <i>World Neurosurgery</i> , 2018, 117, 466.	1.3	2
53	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. <i>Cancer Discovery</i> , 2018, 8, 1006-1025.	9.4	248
54	Non-conventional Inhibitory CD4+Foxp3+PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	16.8	112

#	ARTICLE	IF	CITATIONS
55	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017, 18, 56-61.	6.1	83
56	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017, 545, 60-65.	27.8	1,280
57	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , 2017, 19, 1380-1390.	1.2	35
58	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	9.4	302
59	Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 1989-1996.	1.5	39
60	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 939-946.	1.5	41
61	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489.	7.0	48
62	Increased risk of arterial thromboembolism in older men with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 903-910.	2.5	8
63	Blockade of surface-bound TGF- β 2 on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. <i>Science Signaling</i> , 2017, 10, .	3.6	100
64	Risk of Arterial Thromboembolism in Patients With Cancer. <i>Journal of the American College of Cardiology</i> , 2017, 70, 926-938.	2.8	465
65	Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma. <i>Neuro-Oncology</i> , 2017, 19, 1532-1541.	1.2	51
66	Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. <i>Neuro-Oncology</i> , 2017, 19, 1248-1254.	1.2	79
67	Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 257-264.	1.2	20
68	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	3.0	275
69	Abstract TP72: Pilot Trial of Enoxaparin versus Aspirin in Cancer Patients with Stroke: the TEACH Study. <i>Stroke</i> , 2017, 48, .	2.0	0
70	Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: long-term survival, employment, and performance status of survivors. <i>Neuro-Oncology Practice</i> , 2016, 3, 71-76.	1.6	5
71	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4786-4796.	7.0	95
72	Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. <i>JAMA Internal Medicine</i> , 2016, 176, 1541.	5.1	44

#	ARTICLE	IF	CITATIONS
73	A peripheral blood biomarker estimates probability of survival: the neutrophil-lymphocyte ratio in noncancer patients. <i>Biomarkers in Medicine</i> , 2016, 10, 953-957.	1.4	18
74	Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 57-65.	4.9	18
75	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016, 21, 848-854.	3.7	154
76	R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i> , 2015, 125, 1403-1410.	1.4	267
77	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. <i>Oncologist</i> , 2015, 20, 789-797.	3.7	57
78	Safety of Infusing Ipilimumab Over 30 Minutes. <i>Journal of Clinical Oncology</i> , 2015, 33, 3454-3458.	1.6	24
79	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	1.6	892
80	Clinical trial design for rare cancers: why a less conventional route may be required. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 661-663.	3.1	18
81	Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. <i>Neuro-Oncology</i> , 2014, 16, 829-840.	1.2	198
82	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	7.0	89
83	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2014, 16, 1541-1546.	1.2	12
84	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. , 2013, 1, 20.		31
85	Response to Weltman and Fleury Malheiros, re Lassman et al.. <i>Neuro-Oncology</i> , 2012, 14, 677-678.	1.2	0
86	Initial treatment patterns over time for anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2012, 14, 761-767.	1.2	48
87	When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival. <i>Journal of the National Cancer Institute</i> , 2007, 99, 428-432.	6.3	160
88	Patterns of treatment in older adults with primary central nervous system lymphoma. <i>Cancer</i> , 2007, 110, 1338-1344.	4.1	39
89	Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. <i>Statistics in Medicine</i> , 2007, 26, 2017-2035.	1.6	42
90	Trends in survival from primary central nervous system lymphoma, 1975-1999. <i>Cancer</i> , 2005, 104, 2466-2472.	4.1	106

#	ARTICLE	IF	CITATIONS
91	Likelihood Modelling: A Statistical Perspective on Gene Expression Data Analysis. , 2005, , 361-379.		0
92	An optimal two-stage phase II design utilizing complete and partial response information separately. Contemporary Clinical Trials, 2002, 23, 367-379.	1.9	26
93	Multivariate Prognostic Model for Patients With Thick Cutaneous Melanoma: Importance of Sentinel Lymph Node Status. Annals of Surgical Oncology, 2002, 9, 637-645.	1.5	13
94	A standardization method to adjust for the effect of patient selection in phase II clinical trials. Statistics in Medicine, 2001, 20, 883-892.	1.6	16
95	Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. International Journal of Cancer, 2000, 87, 391-398.	5.1	98
96	Interval estimation of the common odds ratio from (2×2) tables under cluster sampling. , 1999, 18, 1087-1100.		5
97	A Population-Based Study of Treatment and Survival in Older Glioma Patients. JNCI Cancer Spectrum, 0, , .	2.9	4
98	Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment. Oncologist, 0, , .	3.7	0